GSK plc (NYSE:GSK) is one of the 12 best healthcare stocks to buy now. On June 12, the company announced licensing its ...

TV18’s Timsy Jaipuria, Krishna M Ella, Executive Chairman of Bharat Biotech, discusses the growing threat of antimicrobial ...

This collaboration reflects Bharat Biotech’s continued commitment to global public health and equitable vaccine access ...

The partnership includes support for the design of the Phase III trial and assistance in securing external funding.

Hyderabad: Vaccine maker Bharat Biotech International Limited (BBIL) has in-licensed pharma giant GSK's under development ...

Under terms of the deal, Bharat Biotech will lead late-stage development and scale-up of the altSonflex1-2-3 Shigella vaccine ...

India also impacted by Shigellosis, a severe form of bacterial diarrhoea that disproportionately affects children under five in low- and middle-income countries ...

UK pharma major GSK today revealed that it has licensed its Shigella vaccine candidate, altSonflex1-2-3, to India’s Bharat ...

On June 12, the company announced licensing its Shigella vaccine candidate to Bharat Biotech. The licensing is part of the company’s effort to get the vaccine to patients where the pathogen ...

Bharat Biotech has in-licensed GSK's Shigella vaccine candidate, altSonflex1-2-3, aimed at combating Shigellosis in young children in low- and middle-income countries. Following promising early ...

Key TakeawaysThe global vaccines market reached USD 87.57 billion in 2024 and is projected to grow to USD 206.78 billion by 2035, representing a robust CAGR of 9.80%.Increasing prevalence of ...